KPKishan S. Parikh

Kishan S. Parikh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kishan S. Parikh has a total of 127 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension

    by Kishan S. Parikh, Sean Doerfler, Nicholas Shelburne, Karla Rn Kennedy, Jordan Whitson, Talal Dahhan, Terry Fortin, Sudarshan Rajagopal

    Parenteral prostacyclin therapies remain first-line therapy for patients with pulmonary arterial hypertension (PAH) with class IV symptoms. In selected patients who have been clinically stabilized, switching to selexipag, a chemically distinct prostacyclin receptor agonist, may alleviate risks associated with long-term parenteral therapy. We report our experience with transition of patients from parenteral prostacyclin therapy to selexipag. From January 2016 to July 2017, patients with PAH at the Duke University Pulmonary Vascular Disease Center with functional class II symptoms on stable parenteral prostacyclin therapy were offered the opportunity to transition to selexipag. A standardized protocol was developed to guide titration of therapies. Patients underwent pre- and post-transition assessments of hemodynamics, echocardiography, laboratory biomarkers, and functional status. We studied 14 patients with PAH (11 women; median age 53 years) in total. Overall, 13 patients tolerated the switch to selexipag and remained on the drug at study completion, and 1 patient passed away due to progressive liver failure. Surrogate markers including NT-proBNP, 6MWD, RV function, and TAPSE, and right heart catheterization hemodynamics were similar before and after transition. The transition from parenteral prostanoid therapy to oral selexipag was overall well-tolerated in patients with stable PAH and functional class II symptoms. Finally, doses of selexipag up to 3200 μg twice daily were well-tolerated in patients who had been treated with prior parenteral prostacyclins.


  • Monitoring Pulmonary Arterial Hypertension Using an Implantable Hemodynamic Sensor

    by Raymond L. Benza, Mark Doyle, David Lasorda, Kishan S. Parikh, Priscilla Correa-Jaque, Nima Badie, Greg Ginn, Sophia Airhart, Veronica Franco, Manreet K. Kanwar, et al.


  • Echocardiographic Assessment of Right Ventricular Function and Response to Therapy in Pulmonary Arterial Hypertension

    by Nicholas J. Shelburne, Kishan S. Parikh, Karen Chiswell, Linda K. Shaw, Joseph Sivak, Kristine Arges, Jennifer Tomfohr, Eric J. Velazquez, Joseph Kisslo, Zainab Samad, et al.


  • Open Access

    Clinical Features and Outcomes of Patients with Sarcoidosis-associated Pulmonary Hypertension

    by Kishan S. Parikh, Talal Dahhan, Leigh Nicholl, Nicole Ruopp, Gina-Maria Pomann, Terry Fortin, Victor F. Tapson, Sudarshan Rajagopal

    The presence of pulmonary hypertension (PH) significantly worsens outcomes in patients with advanced sarcoidosis, but its optimal management is unknown. We aimed to characterize a large sarcoidosis-associated pulmonary hypertension (SAPH) cohort to better understand patient characteristics, clinical outcomes, and management strategies including treatment with PH therapies. Patients at Duke University Medical Center with biopsy-proven sarcoidosis and SAPH confirmed by right heart catheterization (RHC) were identified from 1990–2010. Subjects were followed for up to 11 years and assessed for differences by treatment strategy for their SAPH, including those who were not treated with PH-specific therapies. Our primary outcomes of interest were change in 6-minute walk distance (6MWD) and change in N-terminal pro-brain natriuretic peptide (NT-proBNP) by after therapy. We included 95 patients (76% women, 86% African American) with SAPH. Overall, 70% of patients had stage IV pulmonary sarcoidosis, and 77% had functional class III/IV symptoms. Median NT-proBNP value was elevated (910 pg/mL), and right ventricular dysfunction was moderate/severe in 55% of patients. Median values for mean pulmonary artery pressure (49 mmHg) and pulmonary vascular resistance (8.5 Woods units) were consistent with severe pulmonary hypertension. The mortality rate over median 3-year follow-up was 32%. Those who experienced a clinical event and those who did not had similar overall echocardiographic findings, hemodynamics, 6MWD and NT-proBNP at baseline, and unadjusted analysis showed that only follow-up NT-proBNP was associated with all-cause hospitalization or mortality. A sign test to evaluate the difference between NT-Pro-BNP before and after PH therapy produced evidence that a significant difference existed between the median pre- and post-NT-Pro-BNP (−387.0 (IQR: −1373.0-109), p = 0.0495). Use of PH-specific therapy may be helpful in selected patients with SAPH and pre-capillary pulmonary vascular disease. Prospective trials are needed to characterize responses to PH-specific therapy in this subset of patients with SAPH.


  • Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF)

    by Marat Fudim, Kishan S. Parikh, Allison Dunning, Adam D. DeVore, Robert J. Mentz, Phillip J. Schulte, Paul W. Armstrong, Justin A. Ezekowitz, W.H. Wilson Tang, John J.V. McMurray, et al.


  • Dose Response of β-Blockers in Adrenergic Receptor Polymorphism Genotypes

    by Kishan S. Parikh, Mona Fiuzat, Gordon Davis, Megan Neely, Penny Blain-Nelson, David J. Whellan, William T. Abraham, Kirkwood F. Adams, G. Michael Felker, Stephen B. Liggett, et al.

    Background In heart failure (HF) with reduced ejection fraction, 2 clinical trials, the BEST (β-Blocker Evaluation of Survival Trial) and HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training), have reported an effectiveness interaction between the ADRB1 (β-1 adrenergic receptor) Arg389Gly polymorphism and β-blockers (BBs). HF-ACTION additionally reported a dose-related interaction of unclear origin. If confirmed and pharmacogenetically resolved, these findings may have important implications for HF with reduced ejection fraction precision therapy. We used uniform methodology to investigate BB dose-ADRB1 Arg389Gly polymorphism interaction with major clinical end points in BEST/bucindolol and HF-ACTION/other BB databases. Methods This was a retrospective analysis of prospectively designed DNA substudies from BEST (N=1040) and HF-ACTION (N=957). Subjects were genotyped for ADRB1 Arg389Gly and ADRA2C (α2C adrenergic receptor) Ins322-325Del. BB dose was defined as either no/...


  • Heart Failure With Preserved Ejection Fraction Expert Panel Report

    by Kishan S. Parikh, Kavita Sharma, Mona Fiuzat, Howard K. Surks, Jyothis T. George, Narimon Honarpour, Christopher Depre, Patrice Desvigne-Nickens, Richard Nkulikiyinka, Gregory D. Lewis, et al.


  • Open Access

    Overdue to understand anticoagulation in pulmonary arterial hypertension

    by Kishan S. Parikh, Michael P. Gray, Lewis J. Rubin, David Badesch, Richard A. Krasuski


  • Representativeness of Medicare Participants in the Jackson Heart Study for African American Medicare Beneficiaries

    by Kishan S. Parikh, Melissa A. Greiner, Wei Wang, Yuan-I Min, Adolfo Correa, Benjamin F. Banahan, Lesley H. Curtis, Adrian F. Hernandez, Emily C. O’brien, Robert J. Mentz

    The Jackson Heart Study (JHS) assesses cardiovascular disease risk factors among African Americans in Jackson, Mississippi. Whether characteristics of JHS participants differ from those of a broader African American population are unknown. In a retrospective observational analysis, we compared characteristics and outcomes of JHS participants 65 years old and older and enrolled in Medicare (n = 1,105) to regional (n = 57,489) and national (n = 95,494) cohorts of African American Medicare beneficiaries. We weighted the regional and national cohorts to match the age and sex distributions of the JHS–Medicare cohort for pairwise baseline comparisons. Outcomes of interest included mortality and Medicare costs. We used Cox proportional hazards models to test associations between cohorts and outcomes. The JHS–Medicare cohort was younger, included more women, and had fewer beneficiaries with dual Medicare–Medicaid eligibility, compared with regional and national Medicare cohorts. The cohort also had lower risks of stroke, lung disease, heart failure, diabetes, and renal disease. Mean Medicare costs were lower ($5,066 [SD = $11,932]) than in the regional ($7,419 [SD = $17,574]) and national ($8,013 [SD = $19,378]) cohorts. The regional and national cohorts had higher mortality (adjusted hazard ratios = 1.52; 95% confidence interval [CI] = 1.31, 1.76; and 1.49; 95% CI = 1.29, 1.73, respectively). Subgroup analysis for dual Medicare–Medicaid eligibility attenuated mortality differences. JHS–Medicare participants had fewer comorbid conditions, better survival, and lower Medicare costs compared with regional and national cohorts. Observed differences may reflect healthy volunteer bias and higher socioeconomic status. See video abstract at, http://links.lww.com/EDE/B235.